Predicting Factors for a Favorable Pathologic Response to Neoadjuvant Therapy in Esophageal Cancer

*Department of Surgery

‡Department of Pathology Rabin Medical Center, Petah Tikva, Israel and The Sackler School of Medicine, Tel-Aviv University

§Division of Oncology, Rambam Health Care Campus, Haifa, Israel and The Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa

†Division of Thoracic Surgery, The cardio-Vascular institute, Baruch-Padeh medical center of the North, Poriya, Israel

O.Z.: First co-author.

The authors declare no conflicts of interest.

Correspondence: Ory Wiesel, MD, Division of Thoracic Surgery, The cardio-Vascular institute, Baruch-Padeh medical center of the North, Poriya, Israel. Lower Galilee 15208. E-mail: [email protected].

留言 (0)

沒有登入
gif